Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
4D Molecular Therapeutics, Inc. (FDMT) Receiveable Turnover data is not available for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$0.04M |
|
$-160.87M |
|
-- |
|
$0.04M |
|
$187.88M |
|
$-187.84M |
|
$26.97M |
|
$-160.87M |
|
$-160.87M |
|
$-160.87M |
|
$-160.87M |
|
$-160.87M |
|
$-160.87M |
|
$-187.84M |
|
$-190.37M |
|
53.94M |
|
53.94M |
|
$-2.98 |
|
$-2.98 |
|
| Balance Sheet Financials | |
$434.93M |
|
$19.53M |
|
$125.45M |
|
$560.38M |
|
$29.15M |
|
-- |
|
$20.63M |
|
$49.78M |
|
$510.61M |
|
$510.61M |
|
$510.61M |
|
45.79M |
|
| Cash Flow Statement Financials | |
$-134.59M |
|
$-302.44M |
|
$337.25M |
|
$249.11M |
|
$149.34M |
|
$-99.77M |
|
$26.12M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.92 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-507678.30% |
|
-507678.30% |
|
-514513.50% |
|
-434778.40% |
|
-434778.40% |
|
$-138.37M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
|
Receiveable Turnover |
-- |
-- |
|
-31.51% |
|
-31.51% |
|
-28.71% |
|
-31.51% |
|
$11.15 |
|
$-2.57 |
|
$-2.49 |
|